Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth
Metrics: PDF 1528 views | HTML 1940 views | ?
Julin S. Wong1,2 Emma Warbrick2, Borek Vojtesk3, Jeffrey Hill4 and David P. Lane1
1 p53 Laboratory, 8A Biomedical Grove, Immunos #06-06, Singapore, Singapore.
2 Epithelial Genetics Group, Medical Sciences Institute, College of Life Sciences and Medicine, Dentistry & Nursing, Dundee, Scotland, UK.
3 Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
4 Experimental Therapeutics Centre, 31 Biopolis Way, Nanos Level 3, Singapore.
David P. Lane, email:
Keywords: c-Met, seeMet 2, monoclonal antibody, temperature sensitive & cryptic epitope
Received: June 4, 2013 Accepted: June 27, 2013 Published: June 29, 2013
c-Met is a tyrosine receptor kinase which is activated by its ligand, the hepatocyte growth factor. Activation of c-Met leads to a wide spectrum of biological activities such as motility, angiogenesis, morphogenesis, cell survival and cell regeneration. c-Met is abnormally activated in many tumour types. Aberrant c-Met activation was found to induce tumour development, tumour cell migration and invasion, and the worst and final step in cancer progression, metastasis. In addition, c-Met activation in cells was also shown to confer resistance to apoptosis induced by UV damage or chemotherapeutic drugs. This study describes the development of monoclonal antibodies against c-Met as therapeutic molecules in cancer treatment/diagnostics. A panel of c-Met monoclonal antibodies was developed and characterised by epitope mapping, Western blotting, immunoprecipitation, agonist/antagonist effect in cell scatter assays and for their ability to recognise native c-Met by flow cytometry. We refer to these antibodies as Specifically Engaging Extracellular c-Met (seeMet). seeMet 2 and 13 bound strongly to native c-Met in flow cytometry and reduced SNU-5 cell growth. Interestingly, seeMet 2 binding was strongly reduced at 4oC when compared to 37oC. Detail mapping of the seeMet 2 epitope indicated a cryptic binding site hidden within the c-Met α-chain.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.